ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique […]
https://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-box-e1478849890427.png134134wp_art_ad-biotechhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngwp_art_ad-biotech2010-09-27 18:09:042014-11-13 18:09:41ARTES steps further into the vaccine business by acquiring Anavax
Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C. The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a […]
Langenfeld and Cairo – ARTES Biotechnology and Rhein Minapharm Biogenetics jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology […]
https://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-box-e1478849890427.png134134wp_art_ad-biotechhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngwp_art_ad-biotech2009-11-16 18:12:252014-11-13 18:12:48ARTES and Rhein Minapharm continue their successful product development collaboration
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
ARTES steps further into the vaccine business by acquiring Anavax
ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique […]
Injectable Sustained Release Formulations of Therapeutic Proteins
Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C. The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a […]
ARTES and Rhein Minapharm continue their successful product development collaboration
Langenfeld and Cairo – ARTES Biotechnology and Rhein Minapharm Biogenetics jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology […]